Panakeia

#JPM25 week is just around the corner and we will be in San Francisco pitching Panakeia at Springboard Enterprises Healthcare & Technology Accelerator Demo Day Showcase Event taking place on January 14th 9-11am PT at the Deloitte offices in San Francisco. It has been a privilege to be part of the accelerator program. A key highlight has been getting access to incredible mentors and networks to grow our business and drive adoption of our ground-breaking AI-enabled multi-omic biomarker profiling platform in the US. We invite you to join us and learn how we bring rapid, digital, intuitive molecular profiling solutions to every clinic, helping healthcare professionals worldwide make informed decisions for their patients. #JPM25 #womenininnovation #moleculardiagnostics #AI #artificialintelligence #cancerdiagnostics #biomarkers #precisionmedicine 

Determining a breast cancer patient’s HER2 status from a biopsy sample is inarguably one of the most consequential tests at the start of the treatment journey as it determines the subsequent therapeutic options available, most importantly those eligible for treatment with novel antibody-drug conjugates. AI-enabled digital pathology solutions have a big role to play in expediting determination of HER2 status, especially when HER2 expression levels are low and status is difficult to determine by eye.  At this year’s San Antonio Breast Cancer Symposium we are proud to have co-authored a study conducted as part of a research partnership to describe and evaluate the agreement of HER2 biomarker assessment across independently developed AI models put together by Friends of Cancer Research. The study concluded that while variability exists, these models routinely determined HER2 status successfully. We are filled with hope and anticipation for the continuation of this study which will inform the future development of AI models and set a gold standard for the ever-evolving landscape in the context of clinical application.   Abstract title: Agreement Across 10 Artificial Intelligence Models in Assessing HER2 in Breast Cancer Whole Slide Images: Findings from the Friends of Cancer Research Digital PATH Project  Abstract no: P2-02-18 Booth: #1433 in the Exhibit Hall, Halls 2-3 Time and date: Poster Session 2, 5:30 – 7:00 p.m. CST, Wednesday, December 11 Read the full abstract here: https://lnkd.in/enX25nD9 #SABCS24 #breastcancer #biomarker #HER2 #cancer #precisionmedicine #moleculardiagnostics

Thank you, Duke Capital Partners for your continued support in our mission to usher a new era of precision treatments for all by bringing rapid, digital, intuitive molecular profiling solutions to every clinic, helping healthcare professionals worldwide make informed decisions for their patients.

This week we are in San Francisco attending the 3rd Danaher Corporation Annual Summit titled “AI-driven Predictive R&D: from Promise to Practice”. This year’s event focuses on how generative and predictive AI, data integration, and knowledge generation are revolutionising biopharmaceutical research and development. Our founder and CEO Pahini Pandya will be on the ground to discuss with industry experts, fellow innovators and other industry stakeholders Panakeia’s contribution to the field. Our  AI-enabled multi-omics platform can detect cancer biomarkers, informing treatment decisions for healthcare professionals and accelerating drug development by enabling patient screening, stratification and monitoring. Find out more about the event here: https://lnkd.in/ek7yB4nN #researchanddevelopment #moleculardiagnostics #AI #precisionmedicine

It’s been six wonderful years since Panakeia was founded. We are thankful for our wonderful team and what we have collectively achieved. Our 6th birthday highlights include: 🧬 Developing a ground-breaking platform for multi-omic biomarker identification for more than 30 cancer types. 🔬 Having two clinical products approved for biomarker identification. 🏥Our products deployed in hospitals in the UK and producing best-in-class results. 🚀 Building a strong research team that has produced state of the art AI-enabled technology. 📈 Growing our team every year bringing in world class talent, driving our mission of bringing rapid, cost-effective molecular profiling to every clinic to help healthcare professionals worldwide make informed decisions for their patients and usher a new era of precision treatments for all. We look forward to many more years of innovation, excellence and camaraderie.

We have landed in India where over the next few days we will engage with a variety of stakeholders in India’s healthcare industry in Mumbai, Bengaluru and Delhi. We are privileged to be part of the 10th UK-India Healthcare Trade Mission organised by the UK Government's Department for Business and Trade and led by Professor Sir Stephen Powis, National Medical Director of NHS England, alongside other innovative UK companies. India is a fast growing economy with an advanced healthcare system which is currently embarrassing digital diagnostics and personalised medicine, making it one of the leaders in the digital transition of healthcare. We look forward to discussing the capabilities of our AI-enabled multi-omics platform for detecting cancer biomarkers, informing treatment decisions for healthcare professionals and accelerating drug development by enabling patient screening, stratification and monitoring. Find out more about the mission here: https://lnkd.in/eX9m7kBU (edited) #trademission #innovation #healthtech #AI #precisionmedicine #biomarkers #personalisedtreatment #digitalhealth

We are proud to be sponsoring this year’s Symposium on Breast Pathology jointly organised by Association of Breast Pathology (ABP) and the British Division of the International Academy of Pathology (BDIAP) and taking place in London on 22-23 November 2024. We are looking forward to meeting with pathologists and other stakeholders to discuss the capabilities of our AI-enabled multi-omics platform for detecting breast cancer biomarkers. Find out more about the even here: https://lnkd.in/eMUZrSPz

Thank you Chloe Roesler and Goddess Gaia Ventures for highlighting Panakeia and our work with breast cancer molecular profiling when asked to list promising femtech startups by Vestbee.  Read the full article below:

On International Pathology Day we pay tribute to the unsung heroes of healthcare, the pathologists. Pathologists play a pivotal role in a patients’ diagnosis and treatment journey. For cancer in particular, a pathologist’s expertise in diagnosing the disease will inform an oncologist’s treatment decision and will help them monitor the disease as it progresses. Watch how patients got a closer look at their cancer as well as the process of diagnosing  through a College of American Pathologists (CAP) pathologist’s initiative: https://lnkd.in/e5-8XQ6x #IPD2024 #pathology

November is lung cancer awareness month. Lung cancer is the most common and deadliest cancer type according to IARC - International Agency for Research on Cancer / World Health Organization. Early, accurate diagnosis can vastly improve outcomes for patients but molecular profiling from biopsy samples can take days or weeks. In cancer, every second counts and can impact the outcome of treatment. AI has the power to deliver cost-effective, rapid molecular profiling results for lung cancer, amongst many other cancer indications. At Panakeia, we are building a software platform that can perform rapid profiling to accelerate diagnosis and precision treatment decision making. Visit IARC’s website to find out more about lung cancer: https://lnkd.in/eiDAq8nV. #lungcancer #earlydiagnosis #moleculardiagnostics #AI #lungcancerawareness